Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (211-220 of 343) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.
Leukemia Research|January 27, 2012
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOPJorge J Castillo, Brady E Beltran, Moo-Kon Song, et al.
American Journal of Hematology|July 11, 2018
Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control studyArtur Jurczyszyn, Jorge J Castillo, David H Vesole, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Cancer Reports (Hoboken, N.J.)|September 22, 2024
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of ChemoimmunotherapyMaría Elena Cabrera, Camila Peña, Valeska Vega, et al.
Leukemia Research|January 29, 2013
Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOPJorge J Castillo, Natalie Sinclair, Brady E Beltrán, et al.
Clinical Hematology International|October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?Anna Suska, David H Vesole, Jorge J Castillo, et al.
Haematologica|August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinibJosephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
American Journal of Hematology|October 29, 2014
Extramedullary Waldenström macroglobulinemiaRanjit Banwait, Yosra Aljawai, Joseph Cappuccio, et al.
Pageof 35

Showing results (211-220 of 343) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.
Leukemia Research|January 27, 2012
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOPJorge J Castillo, Brady E Beltran, Moo-Kon Song, et al.
American Journal of Hematology|July 11, 2018
Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control studyArtur Jurczyszyn, Jorge J Castillo, David H Vesole, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Cancer Reports (Hoboken, N.J.)|September 22, 2024
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of ChemoimmunotherapyMaría Elena Cabrera, Camila Peña, Valeska Vega, et al.
Leukemia Research|January 29, 2013
Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOPJorge J Castillo, Natalie Sinclair, Brady E Beltrán, et al.
Clinical Hematology International|October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?Anna Suska, David H Vesole, Jorge J Castillo, et al.
Haematologica|August 12, 2017
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinibJosephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
American Journal of Hematology|October 29, 2014
Extramedullary Waldenström macroglobulinemiaRanjit Banwait, Yosra Aljawai, Joseph Cappuccio, et al.
Pageof 35